Jean-Louis Bosmans

Jean-Louis Bosmans

Auto-generated profile, based on publicly available information

Jean-Louis Bosmans

Laboratory of Experimental Medicine and Pediatrics, University of Antwerp, Antwerp, Belgium

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2015 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
EGE. M. Gielis
E. M. Gielis
KLK. J. Ledeganck
K. J. Ledeganck
BWBenedicte De Winter
Benedicte De Winter
JFJ. Del Favero
J. Del Favero
JBJ.-L. Bosmans
J.-L. Bosmans
MEMichael Eikmans
Michael Eikmans
After organ transplantation, donor-derived cell-free DNA (ddcfDNA) can be detected in the recipient's blood and urine. Different ddcfDNA quantification techniques have been investigated but a major breakthrough was made with the introduction of digital droplet PCR and massive parallel sequencing creating the opportunity to increase the understanding of ddcfDNA kinetics after transplantation. The observations of increased levels of ddcfDNA during acute rejection and even weeks to months before histologic features of graft rejection point to a possible role of ddcfDNA as an early, noninvasive rejection marker. In this review, we summarize published research on ddcfDNA in the transplantation field thereby elaborating on its clinical utility.

1 September 2003 in Transplantation
Verified
Journal Article
Closed access
PFPeter N Furness
Peter N Furness
CPCarl Philpott
Carl Philpott
MCMary T Chorbadjian
Mary T Chorbadjian
MNMichael L Nicholson
Michael L Nicholson
JBJean-Louis Bosmans
Jean-Louis Bosmans
CCConception Cañas
Conception Cañas
Clinical trials in renal transplantation must use surrogate markers of long-term graft survival if conclusions are to be drawn at acceptable speed and cost. Morphologic changes in transplant biopsies provide the earliest available evidence of damage, and "protocol" biopsies from stable grafts can be used to reduce the number of patients needed in clinical trials. This approach has been inhibited by concerns over safety, but the risk of biopsy of a stable kidney, with no active inflammation or acute functional impairment, has never been formally estimated. In accordance with a predefined set of questions, a retrospective audit of a sequential series of protocol biopsies was performed in four major transplant centers. A total of 2,127 biopsy events were assessed for major complications, and 1,486 were assessed for minor ones. There were no deaths. One graft was lost, under circumstances indicating that the loss should have been prevented. Three episodes of hemorrhage required direct intervention. Three further patients required transfusion. There were two episodes of peritonitis, but one was arguably an unrelated event. All serious complications presented within 4 hr of biopsy. The incidence of clinically significant complications after protocol biopsy of a stable renal transplant is low. Direct benefits to the patients concerned (irrespective of the benefit that may accrue in clinical trials) were not formally assessed but seem likely to outweigh the risk of the procedure. We believe that it is ethically justifiable to ask renal transplant recipients to undergo protocol biopsies in clinical trials and routine care.

1 August 2004 in The Lancet
Verified
Journal Article
Closed access
Giuseppe RemuzziGiuseppe Remuzzi
Giuseppe Remuzzi
MLMariadomenica Lesti
Mariadomenica Lesti
EGEliana Gotti
Eliana Gotti
MGMaria Ganeva
Maria Ganeva
BDBorislav D Dimitrov
Borislav D Dimitrov
PRPiero Ruggenenti
Piero Ruggenenti

1 May 2005 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MMMichael Mengel
Michael Mengel
JBJohannes Bogers
Johannes Bogers
JBJean-Louis Bosmans
Jean-Louis Bosmans
DSDaniel Serón
Daniel Serón
FMFrancesc Moreso
Francesc Moreso
HHHermann Haller
Hermann Haller
C4d staining of renal allografts is regarded as an in situ marker of active humoral rejection. Few data are available about the incidence of C4d deposition in protocol biopsies compared to indication biopsies. To evaluate whether center-specific factors influence the incidence of C4d detection, we performed a multicenter study. From three European centers, 551 protocol and 377 indication biopsies were reclassified according to the updated Banff criteria and stained for C4d. C4d results were recorded as diffuse or focal positive and statistically correlated to clinical parameters, morphology and graft survival. In the protocol biopsies, a diffuse C4d stain was found in 2.0%, and a focal stain in 2.4%. In indication biopsies, 12.2% were diffusely and 8.5% focally C4d positive (protocol:indication p < 0.0001). The incidence of C4d deposition varied significantly between centers, attributable to variable numbers of presensitized patients with more C4d positive indication and protocol biopsies. Diffuse and focal C4d stain correlated with morphology of humoral rejection in protocol as well as in indication biopsies. Protocol biopsies show a significantly lower incidence of C4d deposition than indication biopsies. Subclinical C4d detection in protocol biopsies had no significant impact on allograft survival in our series.

1 January 2017 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
RHRachel Hellemans
Rachel Hellemans
JBJean‐Louis Bosmans
Jean‐Louis Bosmans
DADaniel Abramowicz
Daniel Abramowicz
Induction therapy with antilymphocyte biological agents is widely used after kidney transplantation, most commonly T lymphocyte-depleting rabbit-derived antithymocyte globulin (rATG) or an IL-2 receptor antagonist (IL2RA). Early randomized trials showed that rATG or IL2RA induction reduces early acute rejection, prompting recommendations by Kidney Disease Improving Global Outcomes that IL2RA induction be used routinely in first-line therapy after kidney transplantation, with lymphocyte-depleting induction reserved for high-risk cases. These studies, however, mainly used outdated maintenance regimens. No large randomized trial has examined the effect of IL2RA or rATG induction versus no induction in patients receiving tacrolimus, mycophenolic acid and steroids. With this triple maintenance therapy, the addition of induction may achieve an absolute risk reduction for acute rejection of only 1-4% in standard-risk patients without improving graft or patient survival. In contrast, rATG induction lowers the relative risk of acute rejection by almost 50% versus IL2RA in patients with high immunological risk. These recent data raise questions about the need for IL2RA in kidney transplantation, as it may no longer be beneficial in standard-risk transplantation and may be inferior to rATG in high-risk situations. Updated evidence-based guidelines are necessary to support clinicians deciding whether and what induction therapy is required for their transplant patients today.

12 January 2006 in Allergy
Verified
Journal Article
Open access
PDF file
DED. G. Ebo
D. G. Ebo
JBJ. L. Bosmans
J. L. Bosmans
MCM. M. Couttenye
M. M. Couttenye
WSW. J. Stevens
W. J. Stevens
Anaphylactic and anaphylactoid reactions related to haemodialysis have been increasingly described for almost 3 decades. The majority of these cases used to occur with ethylene oxide sterilized, and complement‐activating cellulose membranes. However, a considerable number of publications have focused on polyacrylonitrile AN69®high flux membranes, angiotensin converting enzyme inhibitors and iron as other important causes of potentially severe haemodialysis‐related anaphylactoid reactions. Clinical manifestations vary considerably and generally do not allow differentiation between IgE‐mediated anaphylaxis and anaphylactoid reactions (e.g. from nonspecific mediator release). Successful management of these patients requires multidisciplinary approach and involves prompt recognition and treatment by the attending physician, and identification of the offending agent(s) with subsequent avoidance of the incriminated compound(s). This review focuses on some major causes of anaphylactoid and anaphylactic reactions during haemodialysis. Special consideration is given to the therapeutic and diagnostic approach.